These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22362859)

  • 1. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids.
    Lötvall J; Bateman ED; Bleecker ER; Busse WW; Woodcock A; Follows R; Lim J; Stone S; Jacques L; Haumann B
    Eur Respir J; 2012 Sep; 40(3):570-9. PubMed ID: 22362859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial.
    Sterling R; Lim J; Frith L; Snowise NG; Jacques L; Haumann B
    Respir Med; 2012 Aug; 106(8):1110-5. PubMed ID: 22520084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma.
    Bernstein DI; Bateman ED; Woodcock A; Toler WT; Forth R; Jacques L; Nunn C; O'Byrne PM
    J Asthma; 2015; 52(10):1073-83. PubMed ID: 26291137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
    Kempsford R; Norris V; Siederer S
    Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.
    Hanania NA; Feldman G; Zachgo W; Shim JJ; Crim C; Sanford L; Lettis S; Barnhart F; Haumann B
    Chest; 2012 Jul; 142(1):119-127. PubMed ID: 22241764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
    Bleecker ER; Lötvall J; O'Byrne PM; Woodcock A; Busse WW; Kerwin EM; Forth R; Medley HV; Nunn C; Jacques L; Bateman ED
    J Allergy Clin Immunol Pract; 2014; 2(5):553-61. PubMed ID: 25213048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial.
    Lin J; Kang J; Lee SH; Wang C; Zhou X; Crawford J; Jacques L; Stone S
    Respir Med; 2015 Jan; 109(1):44-53. PubMed ID: 25524507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.
    Busse WW; Bleecker ER; Bateman ED; Lötvall J; Forth R; Davis AM; Jacques L; Haumann B; Woodcock A
    Thorax; 2012 Jan; 67(1):35-41. PubMed ID: 21828231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy.
    Oliver AJ; Covar RA; Goldfrad CH; Klein RM; Pedersen SE; Sorkness CA; Tomkins SA; Villarán C; Grigg J
    Respir Res; 2016 Apr; 17():37. PubMed ID: 27044326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
    Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
    Lin J; Tang H; Chen P; Wang H; Kim MK; Crawford J; Jacques L; Stone S
    Allergy Asthma Proc; 2016 Jul; 37(4):302-10. PubMed ID: 27401316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
    Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
    Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β
    Devillier P; Humbert M; Boye A; Zachgo W; Jacques L; Nunn C; West S; Nicholls A; Antoun Z; Spinu L; Grouin JM
    Respir Med; 2018 Aug; 141():111-120. PubMed ID: 30053956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids.
    Bleecker ER; Bateman ED; Busse WW; Woodcock A; Frith L; House KW; Jacques L; Davis AM; Haumann B; Lötvall J
    Ann Allergy Asthma Immunol; 2012 Nov; 109(5):353-358.e4. PubMed ID: 23062392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: A systematic review with meta-analysis.
    Rodrigo GJ; Plaza V
    Ann Allergy Asthma Immunol; 2016 Jun; 116(6):565-70. PubMed ID: 27117053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.
    Bateman ED; O'Byrne PM; Busse WW; Lötvall J; Bleecker ER; Andersen L; Jacques L; Frith L; Lim J; Woodcock A
    Thorax; 2014 Apr; 69(4):312-9. PubMed ID: 24253831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.